Related Experiment Video

Updated: Jun 9, 2026

Epigenetic Regulation of Cardiac Differentiation of Embryonic Stem Cells and Tissues
13:03

Epigenetic Regulation of Cardiac Differentiation of Embryonic Stem Cells and Tissues

Published on: June 3, 2016

Epigenetic Regulation in Cardiovascular Diseases: Mechanisms and Therapeutic Targets

Wangzheqi Zhang1, Chenyang Mu2, Rui Zhao3

  • 1School of Anesthesiology Naval Medical University Shanghai China.

Medcomm
|June 8, 2026
PubMed

Insights

Epigenetic mechanisms significantly influence cardiovascular diseases (CVDs). Understanding these epigenetic changes offers new avenues for developing targeted therapies and biomarkers for CVDs.

Area of Science:

  • Cardiovascular biology
  • Epigenetics
  • Genomics

Background:

  • Cardiovascular diseases (CVDs) result from complex genetic and environmental factors.
  • The molecular underpinnings of CVD pathogenesis, particularly epigenetic contributions, are not fully understood.
  • Existing research on epigenetics in CVDs is fragmented, lacking a unified perspective.

Purpose of the Study:

  • To provide a comprehensive overview of epigenetic modulation in cardiovascular diseases.
  • To connect epigenetic dynamics to cardiovascular phenotypes and clinical implications.
  • To explore novel epigenetic biomarkers and therapeutic strategies for CVDs.

Main Methods:

  • Systematic review and integration of fragmented findings on epigenetic mechanisms in CVDs.
  • Analysis of cell type and disease stage-specific epigenetic alterations.
  • Illustration of environmental and lifestyle factor impacts on the cardiovascular epigenome.

Main Results:

  • Epigenetic mechanisms like DNA methylation and noncoding RNAs play crucial roles in cardiovascular development and disease.
  • Environmental and lifestyle factors dynamically remodel the cardiovascular epigenome.
  • Epigenomic plasticity, enhancer control, and network reprogramming are key drivers of CVD remodeling.

Conclusions:

  • Cardiovascular diseases can be viewed as disorders of stabilized regulatory states.
  • A unified understanding of epigenetics in CVDs facilitates the development of precision epigenomic manipulation strategies.
  • This review highlights potential novel epigenetic biomarkers and therapeutic interventions for CVDs.
Keywords:
cardiovascular diseaseschromatin remodelingenhancer rewiringepigenetic regulationnoncoding RNAsprecision epigenetic therapy

Related Concept Videos

Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...